ABBV 8-K filings, explained
Every material Form 8-K AbbVie has filed with the SEC since January 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Briefs on record16since Jan 07, 2026
Latest filingNov 02, 2026leadership
High impact (4-5)10of 16 briefs
TonePositive1Negative4Mixed4Neutral7
earnings 4guidance 4financing 4leadership 2m&a 2
2026
Nov 2, 4:05 PM ET
AbbVie disclosed that Class II director Jennifer L. Davis intends to resign from its Board of Directors, effective November 2, 2026, after her recent appointment as Chief Executive Officer at Align Technology, Inc. The filing states her resignation is not the result of any disagreement with AbbVie on its operations, policies or practices. The change is a board composition update with no financial figures attached.
- Jennifer L. Davis, a Class II director, notified the Board on October 28, 2026 of her intent to resign.
- Resignation is effective November 2, 2026.
- Reason given: her recent appointment as Chief Executive Officer at Align Technology, Inc.
- The filing states there was no dispute or disagreement with AbbVie on its operations, policies or practices.
Read the filing on SEC.gov ↗
Oct 30, 7:51 AM ET
AbbVie announced third-quarter 2026 net revenues of $17.404 billion and diluted EPS of $2.37 on a GAAP basis. The company raised its full-year 2026 adjusted diluted EPS guidance range to $13.95 through $13.99 and increased its quarterly cash dividend by 5.2 percent to $1.82 per share.
- Third-quarter net revenues reached $17.404 billion, representing a 10.3 percent increase on a reported basis.
- GAAP diluted EPS was $2.37, while adjusted diluted EPS was $3.82 for the third quarter ended September 30, 2026.
- Full-year 2026 adjusted diluted EPS guidance was raised to a range of $13.95 to $13.99.
- The quarterly cash dividend was increased by 5.2 percent to $1.82 per share, payable on February 16, 2027.
Read the filing on SEC.gov ↗
Oct 15, 4:00 PM ET
AbbVie expanded its Board of Directors from twelve to thirteen seats on October 14, 2026, and appointed Dr. John M. Carethers as a Class II director. The Board determined he is independent under NYSE standards, and he joins the Public Policy and Sustainability Committee.
- Board size increased from twelve directors to thirteen on October 14, 2026
- Dr. John M. Carethers appointed as Class II director; serves as Vice Chancellor for Health Sciences at UC San Diego
- Carethers named to the Public Policy and Sustainability Committee and deemed independent under NYSE rules
- Compensation as an independent director is disclosed in Exhibit 10.5 to the Form 10-Q for the quarter ended March 31, 2025
Read the filing on SEC.gov ↗
Oct 5, 4:07 PM ET
AbbVie said third-quarter 2026 results will include $216 million in pre-tax acquired IPR&D and milestones expense, which reduces both GAAP and adjusted diluted EPS by $0.11. The company lowered its guidance accordingly: full-year 2026 adjusted diluted EPS is now $13.76-$13.96, and third-quarter adjusted diluted EPS is $3.73-$3.77. Third-quarter figures are preliminary and have not been finalized.
- Q3 2026 acquired IPR&D and milestones expense: $216 million pre-tax, a $0.11 per-share hit to GAAP and adjusted EPS
- Full-year 2026 adjusted diluted EPS guidance: $13.76-$13.96, down from $13.87-$14.07 before the Q3 charge
- Q3 2026 adjusted diluted EPS guidance: $3.73-$3.77, down from $3.84-$3.88 before the charge
- Results for the quarter ended September 30, 2026 remain subject to closing procedures and may differ from these estimates
Read the filing on SEC.gov ↗
Sep 3, 8:47 AM ET
AbbVie completed its acquisition of Apogee Therapeutics on September 3, 2026, paying $135.11 per share in cash, or about $10.9 billion in total equity value. AbbVie reaffirmed its 2026 full-year adjusted diluted EPS guidance of $13.87 to $14.07 and its third-quarter guidance of $3.84 to $3.88, but expects the deal to reduce adjusted EPS by $0.14 in 2026 and about $0.46 in 2027, with accretion beginning in 2032.
- Apogee shareholders received $135.11 per share in cash, for a total equity value of about $10.9 billion.
- Apogee's common stock ceased trading on NASDAQ before market open on September 3, 2026.
- 2026 full-year adjusted diluted EPS guidance of $13.87 to $14.07 was reaffirmed and includes a $0.14 per share dilutive impact from Apogee.
- The acquisition is expected to reduce adjusted diluted EPS by about $0.46 in 2027, with accretion beginning in 2032.
Read the filing on SEC.gov ↗
Aug 18, 4:30 PM ET
AbbVie completed an underwritten offering of nine series of senior notes on August 18, 2026, totaling $10.0 billion in principal across floating rate notes maturing 2028 and fixed rate notes maturing 2028 through 2066. AbbVie expects to use the net proceeds to fund part of the cash consideration for its acquisition of Apogee Therapeutics and related fees, with any remainder for general corporate purposes.
- Nine series of notes totaling $10.0 billion in aggregate principal, registered under AbbVie's Form S-3ASR dated February 14, 2025
- Net proceeds to fund a portion of the cash consideration due to Apogee shareholders and related fees and expenses
- If the Apogee acquisition is terminated or abandoned, AbbVie must redeem most series (not the 2056 or 2066 Notes) at 101% of principal plus accrued interest
- Notes are unsecured and rank equally with AbbVie's existing and future unsecured, unsubordinated debt
Read the filing on SEC.gov ↗
Aug 5, 5:17 PM ET
AbbVie agreed on August 4, 2026 to sell $9.93 billion in net proceeds of senior notes across eight series maturing from 2028 to 2066. The company says it will use the proceeds to fund part of the cash payments for its acquisition of Apogee Therapeutics and for general corporate purposes, including debt repayment or repurchase. The offering adds debt to the balance sheet, but it also reduces commitments under a $10.0 billion term loan facility that was arranged for the Apogee deal.
- Eight series of notes totaling $9.93 billion in estimated net proceeds, including $1.5 billion of 4.875% notes due 2031 and $1.5 billion of 5.300% notes due 2036
- Proceeds are expected to fund part of the cash payments for the Apogee Therapeutics acquisition
- Closing is expected on August 18, 2026, subject to customary closing conditions
- Net proceeds will reduce commitments under the $10.0 billion 364-Day delayed draw term loan facility
Read the filing on SEC.gov ↗
Jul 31, 7:51 AM ET
AbbVie reported second-quarter 2026 net revenues of $16.99 billion, up 10.2% on a reported basis, and adjusted diluted EPS of $3.65, up from $2.97 a year earlier. It lowered its 2026 adjusted EPS guidance to $13.87-$14.07 from $13.91-$14.11, a $0.04 midpoint cut, mainly because of a $0.14 per share dilutive impact from the proposed Apogee Therapeutics acquisition.
- Q2 net revenues were $16.990 billion, up 10.2% reported and 9.5% operational; Skyrizi revenues were $5.505 billion, up 24.4%.
- Q2 GAAP diluted EPS was $2.03 versus $0.52 a year earlier; adjusted diluted EPS was $3.65 versus $2.97.
- 2026 adjusted diluted EPS guidance is now $13.87-$14.07 versus $13.91-$14.11, including a $0.14 dilutive impact from Apogee, partly offset by $0.10 of overperformance.
- AbbVie agreed to acquire Apogee Therapeutics, valued at a total equity value of about $10.9 billion, with closing expected in the third quarter of 2026.
Read the filing on SEC.gov ↗
Jul 6, 4:12 PM ET
AbbVie said its second-quarter 2026 results will include $291 million in pre-tax acquired IPR&D and milestones expense, which lowers both GAAP and adjusted diluted earnings per share by $0.17. The company cut its full-year 2026 adjusted EPS guidance to $13.91-$14.11 from $14.08-$14.28, so shareholders face lower expected earnings for the year. Second-quarter results have not been finalized and may differ from these preliminary figures.
- Q2 2026 acquired IPR&D and milestones expense of $291 million pre-tax, reducing GAAP and adjusted diluted EPS by $0.17
- Q2 2026 adjusted diluted EPS guidance now $3.57-$3.61, down from $3.74-$3.78
- Full-year 2026 adjusted diluted EPS guidance now $13.91-$14.11, down from the $14.08-$14.28 range announced April 29, 2026
- Quarter ended June 30, 2026 results are not final and could differ from the preliminary estimates
Read the filing on SEC.gov ↗
Jun 22, 7:11 AM ET
AbbVie agreed to acquire Apogee Therapeutics for $135.11 per share in cash, a total equity value of about $10.9 billion, according to a June 22, 2026 joint press release. The deal is expected to close in the third quarter of 2026, subject to Apogee shareholder approval and regulatory approvals, and AbbVie expects it to be accretive to adjusted diluted earnings per share beginning in 2032.
- Price: $135.11 per Apogee share in cash; total equity value of about $10.9 billion
- Expected closing: third quarter of 2026, subject to Apogee shareholder approval and regulatory approvals
- Accretion to AbbVie adjusted diluted EPS expected beginning in 2032
- Fairmount Funds Management LLC and Venrock Associates have signed voting agreements supporting the deal
Read the filing on SEC.gov ↗
Apr 29, 7:50 AM ET
AbbVie reported first-quarter 2026 net revenues of $15.002 billion, up 12.4% from a year earlier, and adjusted diluted EPS of $2.65, up 7.7%. GAAP diluted EPS fell 45.8% to $0.39 because of large charges, including a $2.387 billion pre-tax change in fair value of contingent consideration. The company raised its 2026 adjusted diluted EPS guidance to $14.08-$14.28 from $13.96-$14.16.
- Q1 2026 net revenues $15.002 billion, up 12.4% on a reported basis (10.3% operational)
- GAAP diluted EPS $0.39 vs. $0.72 a year earlier; adjusted diluted EPS $2.65 vs. $2.46
- Skyrizi net revenues $4.483 billion (up 30.9%); Rinvoq $2.119 billion (up 23.3%)
- 2026 adjusted diluted EPS guidance raised to $14.08-$14.28 from $13.96-$14.16, including a $0.41 per share acquired IPR&D and milestones charge in Q1
Read the filing on SEC.gov ↗
Apr 3, 4:05 PM ET
AbbVie said its first-quarter 2026 results will include $744 million in pre-tax acquired IPR&D and milestones expense, reducing both GAAP and adjusted diluted EPS by $0.41. Full-year 2026 adjusted EPS guidance falls to $13.96-$14.16 from the $14.37-$14.57 range given on February 4, 2026, and AbbVie says its guidance excludes any such expense incurred after the first quarter. Shareholders face a lower earnings outlook, and the quarter's results have not been finalized.
- Q1 2026 acquired IPR&D and milestones expense of $744 million pre-tax, an unfavorable $0.41 impact on GAAP and adjusted diluted EPS
- Full-year 2026 adjusted diluted EPS guidance now $13.96-$14.16, versus $14.37-$14.57 previously
- Q1 2026 adjusted diluted EPS guidance now $2.56-$2.60, versus $2.97-$3.01 before the charge
- Quarter ended March 31, 2026 results not finalized and may differ from these preliminary estimates
Read the filing on SEC.gov ↗
Mar 4, 4:59 PM ET
On March 4, 2026, AbbVie completed an underwritten public offering of seven series of senior notes, totaling $8.0 billion in principal, maturing between 2028 and 2066. The notes are unsecured and rank equally with AbbVie's existing unsecured debt, so the offering adds to the company's long-term borrowing obligations that shareholders' interests sit behind.
- Seven series issued: $750 million floating rate notes and $1.5 billion 3.775% notes due 2028 among the fixed-rate series, plus notes due 2031, 2033, 2036, 2056 and 2066 with coupons from 4.125% to 5.650%
- Floating rate and 2028 notes mature March 3, 2028; the other series mature March 15 of their respective years
- Notes governed by a Supplemental Indenture No. 12 dated March 4, 2026, with U.S. Bank Trust Company, National Association as trustee
- Offering registered under a Form S-3ASR dated February 14, 2025; prospectus supplement dated February 24, 2026
Read the filing on SEC.gov ↗
Feb 26, 5:14 PM ET
AbbVie agreed on February 24, 2026 to sell seven series of senior notes, with total principal of $8.0 billion, to a group of underwriters led by J.P. Morgan, BofA Securities, Morgan Stanley and Wells Fargo. The company expects net proceeds of about $7.95 billion, which it plans to use mainly to repay amounts outstanding under a $4.0 billion 364-day delayed draw term loan facility maturing in May 2026, of which $2.0 billion is currently outstanding.
- Seven series of senior notes with total principal of $8.0 billion, maturing from 2028 to 2066
- Expected net proceeds of about $7.95 billion after underwriting discounts and estimated offering expenses
- Proceeds planned to repay the $4.0 billion 364-day term loan, of which $2.0 billion is outstanding, and for general corporate purposes
- Closing expected March 4, 2026, subject to customary closing conditions
Read the filing on SEC.gov ↗
Feb 4, 7:54 AM ET
AbbVie reported fourth-quarter and full-year 2025 results on February 4, 2026. Revenue grew in both periods, and fourth-quarter GAAP diluted EPS was $1.02 versus a loss of $0.02 a year earlier, while full-year GAAP and adjusted EPS each fell slightly. The company also issued 2026 adjusted diluted EPS guidance of $14.37 to $14.57, which excludes acquired IPR&D and milestones expense.
- Full-year 2025 net revenues were $61.160 billion, up 8.6% on a reported basis; full-year GAAP diluted EPS was $2.36, down 1.3%, and adjusted diluted EPS was $10.00, down 1.2%.
- Fourth-quarter 2025 net revenues were $16.618 billion, up 10.0%; GAAP diluted EPS was $1.02 versus a $0.02 loss a year earlier, and adjusted diluted EPS was $2.71 versus $2.16.
- Full-year 2025 results include an unfavorable impact of $2.76 per share from acquired IPR&D and milestones expense.
- 2026 adjusted diluted EPS guidance is $14.37 to $14.57.
Read the filing on SEC.gov ↗
Jan 7, 4:08 PM ET
AbbVie said its fourth-quarter 2025 results will include $1.3 billion in pre-tax acquired IPR&D and milestones expense, which lowers both GAAP and adjusted diluted EPS by $0.71. The company's full-year 2025 adjusted EPS guidance now falls to $9.90-$9.94 from $10.61-$10.65 excluding the charge, and results for the quarter have not been finalized.
- Q4 2025 acquired IPR&D and milestones expense: $1.3 billion pre-tax ($1,265 million), reducing EPS by $0.71
- Full-year 2025 adjusted diluted EPS guidance: $9.90-$9.94, including the Q4 expense, versus $10.61-$10.65 previously announced on October 31, 2025 excluding it
- Q4 2025 adjusted diluted EPS guidance: $2.61-$2.65, versus $3.32-$3.36 before the expense; figures are preliminary and subject to closing procedures
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every AbbVie filing is on SEC EDGAR ↗. 8-K briefs of other companies →